Lung Cancer

FOCUS POINTS

1. Epidemiology & Risk Factors

  • NSCLC (~85%) vs SCLC (~15%)
  • Major risk factor: smoking (tobacco)
  • Environmental/occupational exposures: radon, asbestos, air pollution
  • Genetic mutations: EGFR, ALK, ROS1, KRAS

2. Histology & Molecular Testing

3. Staging

4. First-Line Therapy

5. Maintenance & Second-Line Therapy

6. Drug Class & Key Differences

7. Pharmacist-Specific Considerations

  • Dosing adjustments: renal/hepatic function for chemo and TKIs
  • Drug interactions: CYP3A4 (EGFR and ALK TKIs), anticoagulants with chemo
  • Monitoring: CBC, LFTs, ECG, electrolytes, thyroid function, symptoms of immune toxicity
  • Supportive care: antiemetics, hydration (cisplatin), growth factor support if indicated
  • Patient education: oral TKIs, adherence, toxicity recognition

8. High-Yield Exam Points

  • Mutation-directed therapy is first-line if present
  • Histology-specific chemo selection (pemetrexed only in nonsquamous, bevacizumab contraindicated in squamous)
  • SCLC staging dictates therapy (limited vs extensive)
  • Immunotherapy adverse events and monitoring
  • Common first-line chemo regimens and dosing differences (cisplatin vs carboplatin)
Feature Key Points for Oncology Pharmacist
Epidemiology - Leading cause of cancer death worldwide - Risk factors: smoking (primary), radon, occupational exposures, family history
Histology NSCLC (~85%) - Adenocarcinoma: most common, often peripheral, may harbor EGFR, ALK, ROS1, BRAF mutations - Squamous: central, associated with smoking, rarely targetable mutations - Large cell: less common, poorly differentiated SCLC (~15%) - Central, strongly associated with smoking, aggressive, rapid doubling time
Staging - NSCLC: TNM staging I–IV - SCLC: Limited stage (confined to one hemithorax) vs Extensive stage (metastatic)
Molecular Testing (NSCLC, adenocarcinoma) - EGFR, ALK, ROS1, BRAF, KRAS, PD-L1 - EGFR positive: ~10–15% in Caucasians, ~30–40% in Asians - ALK positive: ~3–7% - PD-L1 expression guides immunotherapy use
First-Line Therapy (NSCLC) Nonsquamous: - Driver mutation positive → targeted therapy (EGFR TKI, ALK inhibitor, etc.) - No driver mutations: chemo-immunotherapy (platinum + pemetrexed ± pembrolizumab) Squamous: - Platinum doublet chemo (carboplatin + paclitaxel or gemcitabine) ± immunotherapy
First-Line Therapy (SCLC) Limited-stage: cisplatin/etoposide + concurrent thoracic radiation Extensive-stage: cisplatin/carboplatin + etoposide ± immunotherapy (atezolizumab/durvalumab)
Maintenance Therapy (NSCLC) - Squamous: pembrolizumab, gemcitabine, or docetaxel (switch or continuation) - Nonsquamous: pemetrexed ± immunotherapy
Supportive Pharmacologic Considerations - Monitor myelosuppression with platinum doublets - Renal function critical for cisplatin dosing; carboplatin dosing via AUC - Hepatic function important for TKIs (EGFR, ALK inhibitors) - Drug interactions: TKIs metabolized by CYP3A4 - Immunotherapy: monitor for immune-related adverse events (thyroid, hepatitis, colitis)
Other Clinical Pearls - Smoking cessation is critical - CNS metastases common → consider TKIs with CNS penetration - PCI in SCLC may improve survival - Therapy choice depends on histology, molecular profile, stage, ECOG PS, and comorbidities

Drug Treatment

Drug / Class NSCLC / SCLC Mechanism of Action Indication / Line Key Toxicities / ADRs Special Pharmacist Considerations
Cisplatin NSCLC, SCLC Platinum alkylating agent → DNA crosslinking First-line chemo Nephrotoxicity, ototoxicity, nausea/vomiting, myelosuppression Hydration critical, adjust for renal function, antiemetic prophylaxis
Carboplatin NSCLC, SCLC Platinum alkylating agent → DNA crosslinking First-line chemo Myelosuppression (thrombocytopenia), less nephrotoxic than cisplatin Dose via Calvert formula (AUC), renal function important
Pemetrexed NSCLC (nonsquamous) Antifolate → inhibits thymidylate synthase & folate-dependent enzymes First-line or maintenance Myelosuppression, fatigue, mucositis, rash Vitamin B12 and folate supplementation required, avoid in squamous NSCLC
Paclitaxel NSCLC (especially squamous) Microtubule stabilizer → inhibits mitosis First-line chemo Myelosuppression, neuropathy, hypersensitivity Premedicate with steroids/antihistamines, avoid in severe neuropathy
Gemcitabine NSCLC (especially squamous) Nucleoside analog → inhibits DNA synthesis First-line chemo Myelosuppression, flu-like symptoms, rash Monitor CBC, safe in renal impairment
Etoposide SCLC Topoisomerase II inhibitor → prevents DNA unwinding First-line chemo Myelosuppression, alopecia, hypotension with IV infusion Monitor CBC, infusion hypotension possible
Vinorelbine NSCLC Vinca alkaloid → microtubule inhibitor Adjuvant chemo (cisplatin combo) Myelosuppression, constipation, neuropathy IV or oral formulation, monitor CBC
Bevacizumab NSCLC (nonsquamous) VEGF monoclonal antibody → inhibits angiogenesis First-line + chemo Hypertension, bleeding, thrombosis, proteinuria, GI perforation Avoid in squamous NSCLC, monitor BP, urinalysis
Erlotinib / Gefitinib / Afatinib NSCLC (EGFR+ adenocarcinoma) EGFR TKI → inhibits tyrosine kinase signaling First-line or after chemo in EGFR mutation+ Rash, diarrhea, ILD, hepatotoxicity CYP3A4 metabolism, monitor LFTs, rash may indicate response
Crizotinib / Ceritinib / Alectinib / Lorlatinib NSCLC (ALK+) ALK TKI → inhibits ALK fusion proteins First-line or after ALK inhibitor progression Visual disturbances (crizotinib), GI toxicity, hepatotoxicity, edema, QT prolongation Monitor LFTs, ECG, drug interactions (CYP3A4), CNS penetration differs
Pembrolizumab / Nivolumab / Atezolizumab / Durvalumab NSCLC, SCLC (extensive) PD-1 / PD-L1 immune checkpoint inhibitors → enhance T-cell response First-line (PD-L1+) or after chemo Immune-related AE: thyroiditis, hepatitis, colitis, pneumonitis, rash Monitor LFTs, TSH, symptoms of autoimmunity, may combine with chemo
Topotecan SCLC (second-line) Topoisomerase I inhibitor → inhibits DNA replication Relapsed SCLC Myelosuppression, mucositis, diarrhea Renally cleared, dose adjust for renal function
Atezolizumab + Carboplatin/Etoposide SCLC (extensive) Chemo + PD-L1 blockade First-line Myelosuppression + immune AEs Monitor CBC, LFTs, thyroid, infections
Lorlatinib NSCLC (ALK+) 3rd-gen ALK TKI → CNS-penetrant, active after resistance Post 2nd-gen ALK inhibitor progression Hyperlipidemia, CNS effects, edema Lipid monitoring, drug interactions via CYP3A

Key Differences Tailored for Oncology Pharmacist

  1. Chemotherapy vs Targeted Therapy vs Immunotherapy
    • Chemo: broad cytotoxicity → myelosuppression main concern
    • Targeted TKIs: mutation-dependent efficacy → organ-specific toxicity (LFTs, ECG, rash)
    • Immunotherapy: immune-related toxicities → require monitoring for endocrinopathies, hepatitis, colitis
  2. NSCLC Histology Matters
  3. ALK vs EGFR Therapy
  4. Stage Matters
Category Drug / Class NSCLC / SCLC Indication Key Toxicities / ADRs Pharmacist Notes / Monitoring
Platinum Chemotherapy Cisplatin NSCLC / SCLC First-line Nephrotoxicity, nausea/vomiting, myelosuppression, ototoxicity Hydration critical, antiemetics, monitor renal function
  Carboplatin NSCLC / SCLC First-line Myelosuppression (thrombocytopenia), less nephrotoxic Dose via AUC, monitor CBC and renal function
Antimetabolites Pemetrexed NSCLC (nonsquamous) First-line, maintenance Myelosuppression, mucositis, rash Supplement with B12 & folate, avoid squamous NSCLC
  Gemcitabine NSCLC (esp. squamous) First-line Myelosuppression, flu-like symptoms Monitor CBC, renal safe
Microtubule Agents Paclitaxel NSCLC (esp. squamous) First-line Neuropathy, myelosuppression, hypersensitivity Premedicate with steroids/antihistamines
  Vinorelbine NSCLC Adjuvant chemo Myelosuppression, constipation, neuropathy Monitor CBC, oral/IV options
Topoisomerase Inhibitors Etoposide SCLC First-line Myelosuppression, hypotension (IV) Monitor CBC, infusion rate important
  Topotecan SCLC (relapsed) Second-line Myelosuppression, diarrhea, mucositis Renally cleared, adjust for renal function
Targeted Therapy: EGFR TKIs Erlotinib / Gefitinib / Afatinib NSCLC EGFR+ adenocarcinoma Rash, diarrhea, ILD, hepatotoxicity CYP3A4 metabolism, monitor LFTs, rash may correlate with response
Targeted Therapy: ALK TKIs Crizotinib / Ceritinib / Alectinib / Lorlatinib NSCLC ALK+ Visual disturbances, edema, hepatotoxicity, QT prolongation Monitor ECG, LFTs, CNS activity varies by agent
Anti-angiogenesis Bevacizumab NSCLC (nonsquamous) First-line + chemo Hypertension, bleeding, proteinuria, thrombosis Avoid in squamous NSCLC, monitor BP & urinalysis
Immunotherapy (PD-1/PD-L1) Pembrolizumab / Nivolumab / Atezolizumab / Durvalumab NSCLC / SCLC First-line (PD-L1+) or post-chemo Immune-related: thyroiditis, hepatitis, colitis, pneumonitis Monitor LFTs, TSH, autoimmune symptoms, infection risk
Chemo + Immunotherapy Combo Atezolizumab + Carboplatin/Etoposide SCLC (extensive) First-line Myelosuppression + immune AEs CBC, LFTs, thyroid, monitor infections
Surgery / Radiation Adjunct N/A Limited-stage SCLC Adjuvant N/A Chemo + thoracic radiation standard; consider PCI

Quick Pharmacist Takeaways

  1. Histology matters:
  2. Mutation-directed therapy:
  3. Stage matters for SCLC:
  4. Monitoring priorities:
Category Drug / Regimen Indication / Stage Key Toxicities / ADRs Pharmacist Considerations
NSCLC – Nonsquamous Cisplatin + Pemetrexed Stage IV, no driver mutation Myelosuppression, nephrotoxicity, fatigue, mucositis B12 & folate supplementation, monitor renal function, hydration, antiemetics
  Carboplatin + Pemetrexed Stage IV, no driver mutation Myelosuppression (less nephrotoxic than cisplatin) Dose via AUC, supplement B12 & folate
  Carboplatin + Paclitaxel Squamous or chemo backbone Myelosuppression, neuropathy, hypersensitivity Premedicate with steroids/antihistamines
  Bevacizumab + Chemo Nonsquamous, first-line Hypertension, bleeding, thrombosis, proteinuria Avoid in squamous, monitor BP & urinalysis
NSCLC – Targeted Therapy Erlotinib / Gefitinib / Afatinib EGFR mutation+ Rash, diarrhea, ILD, hepatotoxicity CYP3A4 interactions, monitor LFTs, rash may correlate with response
  Crizotinib / Alectinib / Ceritinib / Lorlatinib ALK+ Visual disturbances, edema, hepatotoxicity, QT prolongation Monitor ECG, LFTs; CNS penetration varies by agent
NSCLC – Immunotherapy Pembrolizumab / Nivolumab / Atezolizumab / Durvalumab PD-L1+ or post-chemo Immune-related: thyroiditis, colitis, hepatitis, pneumonitis Monitor TSH, LFTs, autoimmune symptoms; infection risk
SCLC – Limited Stage Cisplatin or Carboplatin + Etoposide + Thoracic RT Limited-stage SCLC Myelosuppression, nausea, fatigue CBC monitoring, hydration, antiemetics; radiation toxicity
SCLC – Extensive Stage Cisplatin/Carboplatin + Etoposide ± Atezolizumab Extensive-stage SCLC Myelosuppression + immune AEs (if immunotherapy added) CBC, LFTs, thyroid, infection monitoring
SCLC – Relapsed Topotecan Second-line therapy Myelosuppression, diarrhea, mucositis Renal dose adjustment required
Maintenance Therapy (NSCLC) Pemetrexed ± Immunotherapy Nonsquamous Fatigue, myelosuppression Monitor CBC, renal/hepatic function
  Pembrolizumab / Gemcitabine / Docetaxel Squamous Myelosuppression, immune AEs (if pembrolizumab) CBC, LFTs, thyroid monitoring

High-Yield BPS Exam Focus

  1. Histology-driven therapy: pemetrexed only for nonsquamous, avoid bevacizumab in squamous.
  2. Mutation-directed therapy is preferred first-line: EGFR TKI for EGFR+, ALK inhibitors for ALK+.
  3. SCLC staging dictates therapy: limited → chemo + thoracic radiation, extensive → chemo ± immunotherapy.
  4. Immune checkpoint inhibitors: know common immune-related adverse events and monitoring.
  5. Chemotherapy nuances: cisplatin (hydration, nephrotoxicity), carboplatin (AUC dosing), myelosuppression.
  6. Pharmacist roles: dose adjustments, drug interactions, monitoring labs (CBC, LFTs, renal, ECG), patient education.

Here’s a comprehensive pharmacist-focused comparison between NSCLC (Non–Small Cell Lung Cancer) and SCLC (Small Cell Lung Cancer):

Feature NSCLC SCLC
Incidence ~85% of lung cancers ~15% of lung cancers
Histology Subtypes Adenocarcinoma (~40%), Squamous cell carcinoma (~25–30%), Large cell carcinoma (~10–15%) Classic SCLC (~95%), Combined SCLC (~5%)
Growth Rate Relatively slower Very rapid, aggressive
Metastatic Potential Slower to metastasize Early and widespread metastases
Staging TNM system (I–IV) Limited stage vs Extensive stage
Typical Location Peripheral (adenocarcinoma), central (squamous) Central / hilar regions, often near bronchi
Paraneoplastic Syndromes Less common; can include hypercalcemia (PTHrP) in squamous cell carcinoma Common: SIADH (hyponatremia), Cushing’s syndrome, Lambert-Eaton myasthenic syndrome
First-line Therapy – Early Stage Surgery ± adjuvant chemotherapy (platinum doublet), ± radiation Rarely surgery; mainly chemoradiation
First-line Therapy – Advanced / Metastatic Targeted therapy (if EGFR, ALK, ROS1, BRAF V600E, NTRK, KRAS), ± immunotherapy (PD-1/PD-L1 inhibitors), or platinum-based chemo Platinum-based chemotherapy + etoposide; ± immunotherapy (PD-L1 inhibitor: atezolizumab or durvalumab)
Chemo Regimens Cisplatin/carboplatin + pemetrexed (non-squamous), cisplatin/carboplatin + gemcitabine (squamous), ± immunotherapy Cisplatin or carboplatin + etoposide ± PD-L1 inhibitor
Radiotherapy Role Adjuvant for early stage, palliative for advanced Thoracic radiotherapy standard in limited stage; prophylactic cranial irradiation (PCI) often used
Response to Therapy Moderate; targeted therapy and immunotherapy improve outcomes High initial response to chemo/radiation, but relapse is rapid
Prognosis 5-year survival ~25% (all stages combined) Poor; 2-year survival <20% for extensive stage

Pharmacist Considerations

NSCLC:

SCLC:

Summary:

Small Cell Lung Cancer

1. Disease Snapshot

  • Highly aggressive neuroendocrine carcinoma of the lung
  • Accounts for ~15% of lung cancers, almost exclusively in smokers
  • Characterized by rapid doubling time and early metastasis
  • Initial high chemo-sensitivity, but fast relapse is common
  • Two-stage system (practical for treatment planning):
    • Limited Stage (LS-SCLC): confined to one hemithorax and regional lymph nodes (can fit in one radiation field)
    • Extensive Stage (ES-SCLC): disease beyond LS definition (includes distant mets)

2. Treatment Overview SCLC is not typically managed surgically. The backbone is systemic chemotherapy ± radiotherapy ± immunotherapy, with platinum-based doublets as first-line.
A. Limited Stage (LS-SCLC) Goal: Cure, if possible


Standard approach:

Regimens:

Additional step:

  • Prophylactic cranial irradiation (PCI) for patients with good response → reduces brain metastases risk

B. Extensive Stage (ES-SCLC) Goal: Prolong survival, improve quality of life


Standard since 2019: Platinum + Etoposide + PD-L1 inhibitor

C. Relapsed Disease

  • Platinum-sensitive relapse (>90 days from last platinum) → consider rechallenge with platinum doublet
  • Platinum-refractory relapse (<90 days) → non-platinum options:
Toxicity Summary
Agent/Class Dose-Limiting Toxicity (DLT) Other Common Toxicities Pharmacist Monitoring & Prevention
Cisplatin Nephrotoxicity Ototoxicity, peripheral neuropathy, severe N/V, electrolyte wasting (Mg²⁺, K⁺, Ca²⁺), myelosuppression (mild) Pre/post hydration (0.9% NaCl ± mannitol), antiemetic prophylaxis (NK1 + 5-HT3 + dexamethasone), baseline/periodic renal function, electrolytes, audiometry
Carboplatin Myelosuppression (thrombocytopenia) Anemia, neutropenia, N/V (mod–high), hypersensitivity (late cycles) CBC before each cycle, dose via Calvert formula, renal function, infusion reaction precautions
Etoposide Myelosuppression (neutropenia) Alopecia, mucositis, hypotension (rapid infusion), secondary AML (rare) CBC, infusion rate control (≥30–60 min), BP monitoring during infusion
Atezolizumab / Durvalumab (PD-L1 inhibitors) Immune-mediated toxicities Pneumonitis, hepatitis, colitis, thyroiditis, adrenal insufficiency, hypophysitis, rash Baseline & periodic LFTs, TFTs, cortisol; patient education on cough, diarrhea, fatigue, rash; prompt corticosteroid initiation for grade ≥2 events
Thoracic Radiotherapy (LS-SCLC) Esophagitis, pneumonitis Fatigue, skin erythema, cough Monitor swallowing, weight, hydration status, respiratory symptoms; coordinate supportive care with RT team
Prophylactic Cranial Irradiation (PCI) Cognitive decline (late) Fatigue, alopecia, headache, nausea Baseline neurocognitive assessment, counsel on memory changes, manage fatigue, antiemetics for acute symptoms

Non-small cell lung cancer

Definition

  • NSCLC makes up ~85% of all lung cancers.
  • It grows and spreads more slowly than small cell lung cancer (SCLC).
  • Divided into three main histologic subtypes.

Major Subtypes

Common Genetic Mutations

  • EGFR mutation: more common in non-smokers, women, Asians
  • ALK rearrangements: associated with younger, non-smoking patients
  • KRAS mutations: common in smokers; resistant to EGFR-targeted therapy
  • Others: ROS1, BRAF, MET, RET, HER2

Risk Factors

  • Smoking (most significant)
  • Secondhand smoke exposure
  • Environmental exposures (asbestos, radon, air pollution)
  • Genetic predisposition (family history)

Clinical Presentation

  • Often asymptomatic in early stages
  • Later symptoms: Cough, Hemoptysis, Dyspnea, Chest pain, Weight loss, Hoarseness, dysphagia (from tumor compression), Paraneoplastic syndromes (e.g., hypercalcemia in squamous cell carcinoma)

Staging Approach

  • TNM system (Tumor, Node, Metastasis):
    • Stage I–II: localized
    • Stage III: locally advanced
    • Stage IV: distant metastasis
  • Imaging: CT chest, PET-CT, brain MRI (for stage III/IV)
  • Biopsy: confirms subtype and allows molecular testing
  • Mediastinal staging: EBUS, mediastinoscopy as needed

Treatment Options

Depends on stage and molecular profile: